Thanks for the link, immunodoc. Remark from the lighter side of Brilacidin science follows:
I stumbled something interesting over there (meaning the linked web page).
Little bit scrolling gets you to image titled: a review on antibodies and venom peptides as new modalities for targeting ion channels.
It seems that blocking hNav1.7 and 1.8 ion channels are generating interest as pain management solutions. Maybe somebody should take a look at Brilacidin development potential in that business. Brilacidin at 1 micromolar (about 0.6 mg/kg) blocks hNav1.7 by 56 %, and at 10 micromolar hNav1.7 is blocked by 89 % and hNav1.8 by 41 %.
One never knows
Good luck to everybody.
I stumbled something interesting over there (meaning the linked web page).
Little bit scrolling gets you to image titled: a review on antibodies and venom peptides as new modalities for targeting ion channels.
It seems that blocking hNav1.7 and 1.8 ion channels are generating interest as pain management solutions. Maybe somebody should take a look at Brilacidin development potential in that business. Brilacidin at 1 micromolar (about 0.6 mg/kg) blocks hNav1.7 by 56 %, and at 10 micromolar hNav1.7 is blocked by 89 % and hNav1.8 by 41 %.
One never knows
Good luck to everybody.
1